These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 29662195)

  • 1. NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth.
    Seidi K; Jahanban-Esfahlan R; Monhemi H; Zare P; Minofar B; Daei Farshchi Adli A; Farajzadeh D; Behzadi R; Mesgari Abbasi M; Neubauer HA; Moriggl R; Zarghami N; Javaheri T
    Oncogene; 2018 Jul; 37(29):3967-3980. PubMed ID: 29662195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RGD delivery of truncated coagulase to tumor vasculature affords local thrombotic activity to induce infarction of tumors in mice.
    Jahanban-Esfahlan R; Seidi K; Monhemi H; Adli ADF; Minofar B; Zare P; Farajzadeh D; Farajnia S; Behzadi R; Abbasi MM; Zarghami N; Javaheri T
    Sci Rep; 2017 Aug; 7(1):8126. PubMed ID: 28811469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of an Integrin α
    Gai Y; Jiang Y; Long Y; Sun L; Liu Q; Qin C; Zhang Y; Zeng D; Lan X
    Mol Pharm; 2020 Jan; 17(1):349-358. PubMed ID: 31829615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.
    Bieker R; Kessler T; Schwöppe C; Padró T; Persigehl T; Bremer C; Dreischalück J; Kolkmeyer A; Heindel W; Mesters RM; Berdel WE
    Blood; 2009 May; 113(20):5019-27. PubMed ID: 19179306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile.
    Dreischalück J; Schwöppe C; Spieker T; Kessler T; Tiemann K; Liersch R; Schliemann C; Kreuter M; Kolkmeyer A; Hintelmann H; Mesters RM; Berdel WE
    Int J Oncol; 2010 Dec; 37(6):1389-97. PubMed ID: 21042706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A CD13-targeting peptide integrated protein inhibits human liver cancer growth by killing cancer stem cells and suppressing angiogenesis.
    Zheng YB; Gong JH; Liu XJ; Li Y; Zhen YS
    Mol Carcinog; 2017 May; 56(5):1395-1404. PubMed ID: 27991698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
    Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
    Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.
    Curnis F; Arrigoni G; Sacchi A; Fischetti L; Arap W; Pasqualini R; Corti A
    Cancer Res; 2002 Feb; 62(3):867-74. PubMed ID: 11830545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Growth Inhibition via Occlusion of Tumor Vasculature Induced by N-Terminally PEGylated Retargeted Tissue Factor tTF-NGR.
    Brand C; Fröhlich M; Ring J; Schliemann C; Kessler T; Mantke V; König S; Lücke M; Mesters RM; Berdel WE; Schwöppe C
    Mol Pharm; 2015 Oct; 12(10):3749-58. PubMed ID: 26310827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An antimicrobial peptide containing NGR motif has potent antitumor activity against CD13+ and CD13- tumor cells.
    Zhang Z; Hou L; Feng L; Huang S; Luo M; Shao S; Zhang X; Gu S; Zhao X
    Tumour Biol; 2015 Sep; 36(10):8167-75. PubMed ID: 25990455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of antimicrobial peptides containing CisoDGRC in CD13 negative breast cancer cells.
    Hou L; Zhao X; Wang P; Ning Q; Meng M; Liu C
    PLoS One; 2013; 8(1):e53491. PubMed ID: 23326440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo NIRF imaging-guided delivery of a novel NGR-VEGI fusion protein for targeting tumor vasculature.
    Ma W; Li G; Wang J; Yang W; Zhang Y; Conti PS; Chen K
    Amino Acids; 2014 Dec; 46(12):2721-32. PubMed ID: 25182731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo tumor targeting by a NGR-decorated micelle of a recombinant diblock copolypeptide.
    Simnick AJ; Amiram M; Liu W; Hanna G; Dewhirst MW; Kontos CD; Chilkoti A
    J Control Release; 2011 Oct; 155(2):144-51. PubMed ID: 21763734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-Administration of Vadimezan and Recombinant Coagulase-NGR Inhibits Growth of Melanoma Tumor in Mice.
    Daei Farshchi Adli A; Jahanban-Esfahlan R; Seidi K; Farajzadeh D; Behzadi R; Zarghami N
    Adv Pharm Bull; 2021 Feb; 11(2):385-392. PubMed ID: 33880362
    [No Abstract]   [Full Text] [Related]  

  • 15. Addition of an aminopeptidase N-binding sequence to human endostatin improves inhibition of ovarian carcinoma growth.
    Yokoyama Y; Ramakrishnan S
    Cancer; 2005 Jul; 104(2):321-31. PubMed ID: 15952188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells.
    Wang X; Wang Y; Chen X; Wang J; Zhang X; Zhang Q
    J Control Release; 2009 Oct; 139(1):56-62. PubMed ID: 19470394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.
    Schmidt LH; Stucke-Ring J; Brand C; Schliemann C; Harrach S; Muley T; Herpel E; Kessler T; Mohr M; Görlich D; Kreuter M; Lenz G; Wardelmann E; Thomas M; Berdel WE; Schwöppe C; Hartmann W
    Lung Cancer; 2017 Nov; 113():121-127. PubMed ID: 29110838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and activity evaluation of a new 5-fluorouracil prodrug containing an Asn-Gly-Arg(NO2)COOCH3 tripeptide.
    Luan Y; Jing F; Zhang J; Zou M; Wang X; Jia Y; Liu N; Mou J; Xu W
    Protein Pept Lett; 2012 Oct; 19(10):1122-31. PubMed ID: 22512656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcoma.
    Brand C; Greve B; Bölling T; Eich HT; Willich N; Harrach S; Hintelmann H; Lenz G; Mesters RM; Kessler T; Schliemann C; Berdel WE; Schwöppe C
    PLoS One; 2020; 15(2):e0229271. PubMed ID: 32084238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
    Sheng W; Shang Y; Li L; Zhen Y
    Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.